Paiva Carlos Eduardo, Rezende Fabiana Faria, Paiva Bianca Sakamoto Ribeiro, Mauad Edmundo Carvalho, Zucca-Matthes Gustavo, Carneseca Estela Cristina, Syrjänen Kari Juhani, Schover Leslie R
Breast and Gynecology Division, Department of Clinical Oncology, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos, SP, 14784-400, Brazil.
Research Group for Palliative Care and Health-Related Quality of Life (GPQual), Barretos Cancer Hospital, Barretos, SP, Brazil.
Arch Sex Behav. 2016 Nov;45(8):2057-2068. doi: 10.1007/s10508-016-0758-7. Epub 2016 Jun 3.
Sexual dysfunction is a common and distressing consequence of breast cancer (BC) treatment. In the present study, we investigated the sexual functioning of BC patients and its association with women's personal characteristics and cancer treatments. In this cross-sectional study, sexual function was assessed using the Female Sexual Function Index (FSFI). The health-related quality of life (HRQOL) was measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and its breast module BR-23. Of the 235 participants approached, 216 participants were included in the study. Of these, 63 patients reported no sexual activity in the last month and thus were analyzed only in relation to the sexual desire domain of FSFI. A total of 154 (71.3 %) patients were classified with hypoactive sexual desire disorder (HSDD). From those patients reporting sexual activity in the last month, 63.3 % (97 out of 153) were classified with sexual dysfunction. Using hierarchical logistic regression, the variance explained (change in R ) by the addition of body mass index (BMI) and mild to moderate physical activity in the prediction models of sexual dysfunction and HSDD were 6.8 and 7.2 %, respectively. Age, BMI, and physical activity were independently associated with sexual dysfunction and HSDD. Additionally, BC patients with sexual dysfunction reported lower scores on global HRQOL, role functioning, and fatigue. Based on our findings, BC survivors should be encouraged to practice regular physical activity and to lose weight in order to avoid sexual dysfunction. However, future clinical trials are needed to confirm these findings.
性功能障碍是乳腺癌(BC)治疗常见且令人苦恼的后果。在本研究中,我们调查了BC患者的性功能及其与女性个人特征和癌症治疗的关联。在这项横断面研究中,使用女性性功能指数(FSFI)评估性功能。使用欧洲癌症研究与治疗组织(EORTC)QLQ-C30及其乳腺模块BR-23测量健康相关生活质量(HRQOL)。在接触的235名参与者中,216名参与者被纳入研究。其中,63名患者报告在上个月没有性活动,因此仅就FSFI的性欲领域进行分析。共有154名(71.3%)患者被归类为性欲减退障碍(HSDD)。在上个月有性活动的患者中,63.3%(153名中的97名)被归类为性功能障碍。使用分层逻辑回归,在性功能障碍和HSDD预测模型中加入体重指数(BMI)和轻度至中度身体活动所解释的方差(R的变化)分别为6.8%和7.2%。年龄、BMI和身体活动与性功能障碍和HSDD独立相关。此外,有性功能障碍的BC患者在总体HRQOL、角色功能和疲劳方面得分较低。根据我们的研究结果,应鼓励BC幸存者进行定期体育活动并减肥,以避免性功能障碍。然而,需要未来的临床试验来证实这些发现。